Valuation
- Market cap
- 2,113,297,000
- Revenue TTM
- $169,120,000
- Net income TTM
- $-48,830,000
- PE ratio
- 0.00
- Forward PE
- 26.74
- Profit margin
- -28.87%
- Debt to equity
- 0.05
Trading
- Volume
- 35,016,300
- Avg volume
- 2,212,256
- Day's range
- $21.63 – $21.76
- Shares out
- 97,657,000
- Stochastic %K
- 45%
- Beta
- 1.31
- Analysts
- Hold
- Price target
- $20.94
Company profile
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceut...
Show more
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland. As of February 12, 2026, Avadel Pharmaceuticals plc operates as a subsidiary of Alkermes plc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 353 1 901 5201
- Website
- https://www.avadel.com
- Address
- 10 Earlsfort Terrace, Dublin, Ireland
Latest news
No headlines yet.
